Tag
Rajeev Juneja
2 articles
Mankind Pharma Q4 Revenue Up 11.8%, EBITDA Margin 27.1%
Mankind Pharma reported Q4FY26 revenue of ₹3,443 Cr, up 11.8% YoY, with adjusted EBITDA margin expanding 400 bps to 27.1%.
Domestic business grew 13.4% driven by strong performance in cardiac (14.7%)
Mankind Pharma Q4 Revenue Up 11.8% YoY
Mankind Pharma reported Q4 FY26 revenue of ₹3,443 crore, an 11.8% YoY increase, with adjusted EBITDA margins at 27.1%.
Domestic business grew 13.4% YoY, driven by a 190 bps increase in chronic therapy